home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change

 
  April 11, 2014  
     
 
Sheraton Seattle Hotel, 1400 6th Avenue, Seattle, WA 98101
September 15-17, 2014


Tumor collections provide insight into the great variability of cancer, its progression and its response to treatment. Patient xenografts and cell models (PDX) allow researchers to link and integrate information and determine personal variations in cancer molecular profiles. The recent advancements in high-throughput genomics, proteomics and other -omics platforms allow profiling of large numbers of cancer analytes in a single assay. Thus, knowledge of these altered molecular landscapes offers great promise for developing molecular tests to improve cancer diagnosis and optimize treatment. Cambridge Healthtech Institute's Inaugural Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change convenes international oncology experts in the fields of tumor biospecimen research, PDX models, molecular diagnostics/prognostics and pharmacogenomics.
 
 
Organized by: Cambridge Healthtech Institute (CHI)
Invited Speakers:
  • John T. Slattery, Ph.D., Vice Dean, Research and Graduate Education, School of Medicine; Professor, Pharmacology and Medicine, University of Washington School of Medicine
  • Nathan D. Price, Ph.D., Associate Director, Institute for Systems Biology
  • James M. Olson, M.D., Ph.D., Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor, Pediatric Hematology and Oncology, University of Washington; Attending Physician, Seattle Children’s Hospital; Founder, Presage Biosciences
  • Carolyn Compton, M.D., Ph.D., CMO, National Biomarkers Development Alliance; Professor, School of Life Sciences, Arizona State University
  • Noah Hoffman, M.D., Ph.D., Assistant Professor, Laboratory Medicine, University of Washington
  • Colin C. Pritchard, M.D., Ph.D., Assistant Professor and Associate Director, Genetics and Solid Tumors Laboratory, Laboratory Medicine, University of Washington
  • Chad R. Borges, Ph.D., Assistant Professor, Chemistry and Biochemistry, The Biodesign Institute – Center for Personalized Diagnostics, Arizona State University
  • Rajiv Raja, Ph.D., Group Leader, Clinical Assays and Technologies Group, Oncology Biomarker Development, Genentech, Inc.
  • Kai Wang, Ph.D., Principal Scientist, Oncology Research Unit, Pfizer, Inc.
  • Ken C.N. Chang, Ph.D., Clinical Assay Development and Outsourcing Lead, Clinical Biomarkers and Diagnostics, Merck & Co., Inc.
  • Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc.
  • Timothy Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
  • Yuzhuo Wang, Ph.D., Associate Professor, Urologic Sciences, University of British Columbia
  • Mayumi Fujita, M.D., Ph.D., Associate Professor, University of Colorado Denver School of Medicine
  • Michael Bouvet, M.D., Professor, Surgery; Director, Endocrine Surgery; Co-Director, GI Cancer Unit, Moores Cancer Center, University of California, San Diego
 
Deadline for Abstracts: ---
 
Registration: Register now
E-mail: kwaterman@healthtech.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.